Extrapulmonary Tuberculosis in Bangladesh:A Comprehensive Review
DOI:
https://doi.org/10.3329/jom.v27i1.88277Keywords:
Extrapulmonary tuberculosis; Bangladesh, Gene Xpert, Lymph node TB, Drug Resistance, Tuberculosis EpidemiologyAbstract
Extrapulmonary tuberculosis (EPTB) represents a major but under-recognized element of the tuberculosis (TB) burden in Bangladesh. Although pulmonary TB (PTB) remains the dominant form of the disease, EPTB accounts for a notable proportion of national TB cases, ranging from 15–30% based on hospital and community-level studies. EPTB manifests in variegated anatomical sites—including lymph nodes, pleura, abdomen, bones, urogenital tract, and the central nervous system—often presenting with nonspecific symptoms that overlap with malignancy, autoimmune disorders, or bacterial infections.These diagnostic challenges combined with the paucibacillary nature of EPTB, complicate clinical evaluation and contribute to delays in management. Recent improvements in molecular diagnostics such as Gene Xpert MTB/RIF have enhanced case detection; however, access remains uneven across Bangladesh, especially in rural and district-level facilities.
This review synthesizes the current evidence on extrapulmonary tuberculosis (EPTB) in Bangladesh, covering epidemiology, risk factors, pathogenesis, clinical presentation, diagnosis, treatment, and systemic challenges. It highlights local research published in BanglaJOL, National TB Program (NTP) data, tertiary hospital studies, and WHO guidance adapted to the Bangladeshi context.Although less common than pulmonary MDR-TB, drug-resistant EPTB presents significant clinical and public health challenges. Reducing EPTBrelated morbidity and long-term complications requires multisectoral strategies, which includes enhanced laboratory capacity, standardized diagnostic protocols, decentralized molecular testing, and targeted clinician training. This review seeks to assist clinicians, researchers, and policymakers by consolidating current knowledge and identifying key gaps and priorities for future action.
J MEDICINE 2026; 27(1): 40-48
Downloads
12
10
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).